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Carcinoma of the pancreas is the cause of death in approximately
7000 patients each year in the UK (Black et al, 1997). At diag-
nosis, fewer than 20% of patients have lesions suitable for poten-
tially curative surgical resection. However, even in this favourable
group, the 5-year survival is only around 10% (Ahlgren et al,
1992). Of the patients who are inoperable, the median survival
time is 4–6 months (Prott et al, 1997). Palliative chemotherapy is
generally offered to fit patients (performance status of 2 or less).
This approach is justified by two recent studies comparing
chemotherapy and best supportive care (BSC). Palmer et al (1994)
found a median overall survival of 8 months in patients treated
with FAM chemotherapy (5-FU (5-fluorouracil), adriamycin and
mitomycin-C) compared with 3.5 months in patients receiving
BSC. Glimelius et al (1996) randomized 93 patients with inoper-
able pancreatic and biliary carcinoma to receive chemotherapy or
BSC and found a median overall survival of 6 months in the
chemotherapy group, with a median overall survival of 2.5 months
in the BSC arm. They also reported an improved quality of life
(QoL) in the treatment arm. Other groups have investigated the
impact of chemotherapy on QoL. At the Royal Marsden Hospital,
Nicolson et al (1995) found an objective radiological response in
16% of patients treated with infusional 5-FU and cisplatin with
34% of patients reporting an improved performance status (PS). In
particular, 60% had a reduction in pain, 70% reported a reduction
in nausea and vomiting and 91% of patients had a reduction in
symptoms of reflux. Burris et al (1997) found 24% of patients
receiving gemcitabine had a clinical benefit (defined as a decrease
in pain and analgesic intake, increase in weight and improved
performance status), compared with 4.8% in patients treated with
5-FU (P = 0.0022). The objective response, however, was only
5.4% in the gemcitabine arm as compared with 0% for the 5-FU
arm. The median survival was 5.65 months with gemcitabine and
4.41 months with 5-FU (P = 0.0025). Thus it can be seen that
objective response, as assessed by conventional radiographic tech-
niques, may not always correlate with patient survival or sympto-
matic response. Objective evaluation of response in pancreatic
cancer is often difficult. Pancreatic tumours less than 3 cm often
cause minimal distortion of the pancreatic architecture and may
remain iso-dense to normal pancreatic tissue. A proportion of
tumours are diffuse and have irregular, indistinct tumour borders.
There is often associated necrosis, abcess and pseudocyst forma-
tion, and biopsies often reveal a mixture of tumour cells, inflam-
matory tissue and fibrosis (Wittenburg et al, 1982). What is
required is an early predictor of response in order to avoid any
unnecessary toxicity, and to assist in a rational treatment plan.
Positron emission tomography (PET) using 18-fluoro-deoxy-
glucose (FDG) is becoming an increasingly important tool in the
management of various cancers. Tumours show enhanced utiliza-
tion of glucose compared with normal tissue as a result of a
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Summary Carcinoma of the pancreas is an aggressive tumour with an extremely poor prognosis. Recent studies have shown that
chemotherapy can improve survival as well as quality of life. Since the prognosis is generally poor, the identification of early responders to
chemotherapy is important to avoid unnecessary toxicity in patients who are not responding. Response assessment by conventional
radiographic methods is problematical because treatment induces fibrosis and makes tumour measurements difficult. The aim of this pilot
study was to assess 18-fluoro-deoxy-glucose positron emission tomography (FDG-PET) as an early marker of the benefit of chemotherapy.
Eleven patients with histologically proven adenocarcinoma of the pancreas were treated with protracted venous infusional 5-fluorouracil (PVI
5-FU) alone or PVI 5-FU and mitomycin C (MMC). FDG-PET scans were performed prior to and at 1 month following the commencement of
chemotherapy. FDG uptake was compared with the tumour dimensions measured on a computer tomographic (CT) scan. Patients were
followed up for relapse, death and symptomatic response. Three of the 11 patients had no measurable FDG uptake prior to chemotherapy. Of
the eight patients who had measurable uptake prior to treatment, seven had a reduction in uptake at 1 month. Six out of the 11 patients had
no measurable FDG uptake at 1 month. The overall survival (OS) in these patients ranged from 124 to 1460 days, with a median of 318.5
days. This was superior in comparison to patients who had residual FDG uptake at 1 month (median survival 318.5 days vs 139 days;
P = 0.034) and there was a trend to improved symptoms (84% [5/6] vs 20% [1/5]; P = 0.13). There was no statistically significant correlation
between best CT response and FDG uptake at 1 month. These results suggest that the absence of FDG uptake at 1 month following
chemotherapy for carcinoma of the pancreas is an indicator of improved overall survival. This suggests that FDG-PET may be superior to
response assessment by conventional radiographic methods and FDG-PET may have the potential to help make difficult treatment decisions
in the management of pancreatic cancer. Larger prospective studies are required to confirm this finding. © 2000 Cancer Research Campaign
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doi: 10.1054/ bjoc.2000.1166, available online at http://www.idealibrary.com on number of factors, including up-regulation of hexokinase, decreased
glucose-6-phosphatase activity and changes in the levels of Glut
membrane transporters, especially Glut 1 (Higashi et al, 1997;
Reske et al, 1997). Higashi et al, found raised Glut-1 expression in
26 out of 28 malignant pancreatic tumours (88%). The uptake of
FDG is similar to that of glucose but, due to differences in the
further metabolic profile (including slow dephosphorylation
compared to glucose), there is enhanced intracellular retention.
FDG-PET has been used in the detection and staging of various
cancers and has proven benefit for the detection of recurrent disease.
A number of small studies have looked at the effect of therapy
induced changes in FDG uptake. Finlay et al (1996) at this centre
investigated the response to chemotherapy of liver metastases in
patients with colorectal cancer. They found that the 4- to
5-week tumour to normal liver (T:L) ratio was able to discriminate
response from non-response both in a lesion-by-lesion and overall
patient response assessment. Other studies have substantiated these
results (Wahl et al, 1991; Okazumi et al, 1992; Haberkorn et al,
1993; Hoekstra et al, 1993; Okada et al, 1994a). A recent European
PET oncology workshop examined the collective experience of
several European centres. It concluded that changes in the uptake of
FDG following one or two cycles of chemotherapy, compared with
pretreatment uptake, may be able to predict clinical outcome and
that the greater the decrease in post-therapy uptake, the better the
response (Price and Jones, 1995). FDG-PET has also been used in
the evaluation of pancreatic cancer. Bares et al (1994) reported that
they were able to detect 24 out of 27 pancreatic cancers on visual
assessment of FDG-PET scans in patients who had pancreatic
masses on CT scan, where they took focal FDG uptake to represent
malignancy. They found a positive predictive value (PPV) for
detecting cancer of 92%, and a negative predictive value (NPV) of
85%. Quantification (by calculation of the differential-uptake-ratio
or ‘DAR’) did not improve their interpretation over visual assess-
ment. Zimny et al (1997) assessed 106 cases of pancreatic mass with
FDG-PET. Visual interpretation gave them 63 out of 74 true posi-
tives, and 27 out of 32 true negatives. The overall sensitivity was
85%, with a specificity of 84%. In euglycaemic patients they found
the sensitivity of PET to be 98% in detecting pancreatic cancer.
Inokuma et al (1995) found that FDG-PET in histologically proven
pancreatic cancer gave a sensitivity of 96%, both qualitatively by
visual assessment (focal FDG uptake representing malignancy) and
quantitatively (by calculation of the standardized-uptake-value or
‘SUV’).
Objective response in pancreatic cancer by conventional radio-
graphic methods is often problematical; the aim of this pilot study
was to investigate the feasibility of FDG-PET in assessing the
clinical benefit of chemotherapy. Due to the well-documented
poor correlation between conventional radiological techniques and
response, overall survival is the optimum measure of the benefit of
treatment. Therefore the correlation between FDG uptake
following the commencement of chemotherapy and survival was
taken as the primary end point of this study. In addition the corre-
lation between symptomatic response and radiological response
was examined as secondary end points.
MATERIALS AND METHODS
Patients
Patients were recruited prospectively over an 8-month period
between March and November 1995. Five patients were treated
with infusional 5-FU alone and six patients were treated with
infusional 5-FU and MMC. This was part of a study protocol
approved by our Institutional committees on clinical research and
patient ethics. Every 6 weeks, symptoms were recorded using a
protocol trial questionnaire. FDG-PET scans were performed prior
to, and at 1 month following, the start of therapy. CT scans were
performed prior to treatment, and at 1, 3, 6, 12 and 24 months
following the start of treatment and patients were assessed for
response according to WHO criteria (Miller et al, 1981). Personnel
reading the CT scans were blinded to the clinical and PET
data. After completion of treatment patients were followed up
3-monthly in the outpatient department and monitored for signs of
relapse. Relapse was defined using standard clinical and radio-
logical criteria. The elapsed time from finishing treatment to
relapse and/or death was recorded.
FGD-PET
List mode data were acquired on the MUP-PET positron camera.
This consists of two large area multiwire proportional chambers
mounted on a rotating gantry (Marsden et al, 1989). These data
were backprojected into a 643 matrix, with cubic voxel dimensions
of length 0.6 cm. Back-projected images were attenuation and
scatter corrected and deconvolved with an experimentally deter-
mined point spread function. The MUP-PET positron camera has
an axial-field-of view (FoV) of 30 cm but in order to satisfy the
spatial invariance criterion needed for the three-dimensional back-
projection and deconvolution image reconstruction method only
the central 15 cm of this axial FoV was used here. A reconstructed
spatial resolution of 6 mm can be achieved when imaging a point
source but, due to the low camera sensitivity, a Hanning filter with
a frequency cut-off of 0.4 cm–1 was used in this study. With this
filter the spatial resolution (FWHM) is ~2 cm. This clearly would
have an effect on the absolute quantification of small tumours due
to the partial volume effect.
Patients were fasted for at least 4 h prior to the scan. An admin-
istration of 50–150 MBq 18FDG was given 1 h prior to the scan.
Scans were acquired for 30–45 min, enabling 1.5 million
coincidence events to be collected. Patients were reproducibly
positioned on the couch using a laser initially focused on the 
xiphisternum.
Where uptake corresponded to radiographic abnormality, region
of interest (ROI) analysis was carried out on a volume of 
4  ´ 4 ´ 1 voxels (0.216 cm3) surrounding the area of maximum
intensity on each scan. The whole lesion was not defined due to
the indeterminacy of delineating the boundary. Defining a region
of maximum intensity enabled volumes to be compared consis-
tently between studies. Background values were determined from
undefined tissue obtained contra-laterally where ROIs were again
of the same volume as for the tumour ROIs.
Tumours were located on the PET images by reference to the
known anatomical location at the centre of the field of view.
Tumours were also localized by their spatial relationship to the
kidneys. To aid tumour localization, image registration with CT
data was carried out for five patients using a point-based method
with in-house software (Flux, 1995). For this, external markers
were used, comprising of perspex discs containing a cavity which
was filled with Ge-68 for the FDG scans and with a solution of
BaCl2 for the CT. In those cases where image registration was
carried out, the average accuracy was 8 mm between the PET and
CT, determined as the rms (root mean square) distance between
corresponding pairs of markers.
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and radiological response and survival data.
This study was approved by our Institutional committees
on clinical research and patient ethics, and received ARSAC
certification.
Statistical analysis
Categorical data were examined using c2 test. Fisher’s Exact test
was used where expected cell counts were less than five. Survival
curves were calculated using the methods of Kaplan and Meier,
and compared using the log-rank test.
RESULTS
Eleven patients (seven men and four women) with histologically
proven adenocarcinoma of the pancreas participated in this study.
The ages ranged from 34 to 69 years, with a median of 57 years,
and a mean of 54.4 years. Patient data are listed in Table 1. During
the period of the study all patients relapsed and all but one patient
died. The overall survival (OS) ranged from 84 days to 1460 days
(1 patient alive at the time writing) with a median of 242 days. The
progression-free survival (PFS) ranged from 49 to 497 days, with a
median of 123 days.
PET response (Table 2)
Of the 11 patients who had FDG-PET scans, eight had a tumour-
to background (T/B) ratio prior to treatment greater than 1. One
patient had increased uptake in the pancreas but the volume was
too small to extract reliable statistics. Eight patients demonstrated
a reduction in FDG uptake a month after the start of treatment, and
six patients had no measurable FDG uptake at this time. One
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Figure 1 A 34-year-old female with adenocarcinoma of the pancreas. (A) Pretreatment CT demonstrating a large mass in the head of the pancreas. 
(B) Pretreatment FDG-PET scan showing physiological FDG renal uptake and FDG uptake in the area of the pancreatic mass seen on the CT. (C) CT scan after
1 month of 5-FU and MMC chemotherapy with partial response by CT criteria. (D) FDG-PET scan after 1 month of chemotherapy shows continued metabolic
activity in the tumour. The ROI analysis shows no significant decrease in FDG uptake in the tumour despite an apparent visual decrease – see Table 2patient had an increase in FDG uptake at 1 month (Figure 1). The
apparent visual decrease in uptake is due to the tumour intensity
relative to the kidneys in that slice. Objective ROI analysis
however does show an increase in tumour/background activity as
given in Table 3. However, within the errors of the measurements,
this is compatible with no fall in glucose uptake.
The T/B values quoted in Table 2 may be considered to be semi-
quantitative in that they quantify the relative uptake between pre-
and post-therapy scans of a patient but do not give absolute uptake
values.
The median OS in the 8 patients who had a PET response was 225
days (range 84–1460 days). The median PFS was 99.5 days (range
49–468 days). The median OS in the patients with no reduction in
FDG uptake was 245 days (range 139–553 days), and the median
PFS was 175 days (range 123–497 days). However, two of the three
patients who had no FDG uptake reduction, had no FDG uptake
prior to treatment suggesting low metabolic activity.
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Table 1 Patient data
No. of patients 11
Median age, years 57
Sex
Male 7
Female 4
Treatment
PVI 5-FU 5
PVI 5-FU and MMC 6
Locally advanced 6
Metastatic 5
Size of primary (mm)
Range 20–130
Mean 52.4
Table 2 Pre- and post-treatment tumour-to-background values ± s.d.
Pretreatment Post-treatment Ratios
Patient no. tumour-to-background ratio tumour-to-background ratio Pre/Post
1 1.40±0.12 1.83±0.32 0.76±0.15
2 3.25±1.00 2.66±0.66 1.22±0.48
3 1.77±0.45 1.45±0.45 1.22±0.48
4 2.18±0.25 1.72±0.35 1.27±0.30
5 1.81±0.26 1.15±0.20 1.58±0.36
6 1.77±0.54 1.00 NA
7 1.87±0.24 1.00 NA
8 1.88±0.32 1.00 NA
9 a 1.00 NA
10 1.0 1.00 NA
11 1.0 1.00 NA
a Positive, but volume too small to extract reliable statistics.
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Figure 2 The survival curves of patients with or without FDG uptake at 1 month after the start of treatment. This figure demonstrates that patients who had no
uptake at 1 month had a statistically significant increased overall survival compared to patients with residual uptake (P = 0.034)In the six patients who had no detectable activity at 1 month, the
median OS was 318.5 days (range 124–1460 days). The median
PFS was 216 days (range 78–497 days). In the patients who had
residual FDG uptake at 1 month the median OS was 139 days
(range 84–242 days). The median PFS was 106 days (range
49–202 days). There was a statistically significant difference in
median OS between those patients who had no FDG uptake at one
month compared with those patients who had residual activity
(P = 0.034) (Figure 2)
Radiological response (Table 3)
Of the 11 patients, only one patient had a radiological response at
the time of the post-treatment PET scan at 1 month (compared
with seven who had a PET response). Three further patients had a
radiological response by CT criteria, all at 3 months from the
commencement of treatment. In all, four patients had a radiolog-
ical partial response (PR) to treatment. Of these four patients, three
also had a reduction in FDG uptake following treatment. Of the
three patients who had either an increase or no change in the FDG
uptake following therapy, only one had a radiological partial
response. In patients with a radiological response the median PFS
was 335 days (range 123–468 days). The median OS was 261 days
(range 139–1460 days). In patients with no radiological response
the median PFS was 78 days (range 49–497 days). The OS was
208 days (range 84–553 days). There was no statistically signifi-
cant correlation between best CT response and FDG uptake at 
1 month. Radiological response did not significantly predict for
OS or PFS at 1 month.
Symptomatic response (Table 4)
Five of the six patients who had no FDG uptake at 1 month post-
treatment reported a subjective improvement in their symptoms
following treatment. Four of these patients had abdominal pain
that resolved completely following therapy. Three out of these six
patients became completely asymptomatic on therapy, having
previously reported symptoms ranging from reflux oesophagitis to
abdominal pain. The one patient who had no change in their symp-
toms initially reported only reflux oesophagitis, which continued
despite treatment.
Only one of the five patients (patient 5) who had continuing
FDG uptake at 1 month reported an improvement of their symp-
toms. Interestingly this patient had a large drop in FDG uptake
following treatment with a pre-/post-treatment ratio of 1.6. The
remaining four patients reported no improvement in their symp-
toms. There appears to be a trend towards correlation between
FDG uptake at 1 month and symptoms that fails to reach statistical
significance (P = 0.134).
DISCUSSION
Objective monitoring of the effectiveness of new cancer treat-
ments is essential if these treatments are to become widely accept-
able. The ability to predict therapeutic response early during a
course of treatment for pancreatic cancer is important since prog-
nosis is poor, lifespan limited and toxicity in non-responding
patients is not acceptable. Currently, CT is the accepted method of
assessing therapeutic response of pancreatic cancer but has a
number of important limitations. These include the inability to
clearly outline tumour borders for measurement purposes in
responding patients and complex anatomical relationships.
Furthermore CT is anatomical and yields no information on
tumour metabolism or on the functional effects of treatment (e.g.
vascular shut-down, apoptosis etc). FDG-PET has previously been
shown to be a useful imaging technique in assessing response to
treatment in other cancers.
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Table 3 Patient treatment, CT response and survival
Patient no. Age Sex Metastatic Site Size Chemotherapy CT Best CT PFS OS
disease (mm) response response (days) (days)
at 1/12
1 34 F No Head 45´60 5FU+MMC PR PR 123 139
2 53 M Yes Tail 130´110 5FU+MMC SD SD 106a 106
3 69 M Yes Head 30´40 5FU+MMC SD SD 49 84
4 47 F No Head 42´55 5FU+MMC SD SD 86 208
5 59 M No Head 50´30 5FU+MMC SD PR 202 242
6 38 M Yes Head 30´45 5FU SD PR 468 b
7 63 F Yes Head 20´31 5FU SD SD 78 124
8 52 M No Head 40´40 5FU+MMC SD PR 257 280
9 57 F No Head 30´35 5FU SD SD 93 357
10 62 M Yes Head 50´40 5FU SD SD 175 245
11 65 M No Head 28´40 5FU SD SD 497 553
a Patient no. 2 died from a gastrointestinal bleed. b Patient still alive at time of writing.
Table 4 FDG, CT and symptomatic response
FDG uptake at 1/12 No FDG uptake at 1/12
Symptomatic response 1 4
No Symptomatic response 5 1
P = 0.134 (Two-tailed Fisher’s exact test)
CT response 2 3
No CT response 2 4
P = 0.81 (one-tailed Fisher’s exact test)Our results show that following treatment there was a reduction
in FDG uptake in seven out of the 11 patients studied. In this
patient group there was a median survival of 242 days and an
overall response rate (using radiological criteria) of 36% (four out
of 11 responders) which when compared to historical data of
patients receiving best supportive care only, suggests a favourable
response to treatment. Interestingly, of the seven patients who had
a reduction in FDG uptake in their post-therapy PET scan, only
three had a CT response overall and only one at the time of the
PET scan. This implies that FDG PET may be superior as an early
predictor of response than CT. In addition there was no statistically
significant correlation between best CT response and FDG uptake
at 1 month following the commencement of treatment.
At 1 month following the start of treatment six patients had no
detectable FDG uptake. This patient group had a statistically
significant improved OS (P = 0.019) when compared to patients
with residual FDG uptake. The improved median survival in-
patients with no FDG uptake at 1 month is not explained by the
absence of metastatic disease. Four of the six patients with no
FDG uptake had metastatic disease, compared with none of the
patients with residual FDG uptake.
Five of the six patients with no FDG uptake had a symptomatic
improvement, compared with only one of the five patients with
residual activity. This is not explained by different toxicity profiles
of the two chemotherapeutic regimens, since previous work has
shown no significant difference in toxicity between 5-FU alone
and 5-FU with MMC (Ross et al, 1997). Although this result
did not reach statistical significance (P = 0.134) the trend is
encouraging.
One other interesting possibility to arise from this study is that
pretreatment PET scans may be able to predict for tumour behav-
iour. Three patients had no measurable FDG uptake in their
pretreatment scan, and had an OS of 357, 245 and 553 days respec-
tively (the median survival of all patients being 242 days). It
would be a reasonable assumption that low uptake of FDG corre-
lates with low metabolic activity, and as such may represent a
favourable prognostic factor. 
Previous work has demonstrated that pretreatment FDG PET
scans in different tumour types may be able to predict tumour
behaviour and prognosis. However, many of these studies suffer
from small numbers and a heterogeneity of histological grades as
well as treatment options. Okada et al (1994b) reported a statisti-
cally significant decreased OS in patients with a high DAR in their
series of 34 patients with lymphoma. However, treatment varied
between radiotherapy (RT), chemotherapy, or a combination of
both. They also studied a variety of different histological
subgroups. Ahuja et al (1998) performed a retrospective study of
155 patients with newly diagnosed non-small-cell lung carcinoma
prior to treatment. They reported that a low SUR (standardized
uptake ratio) was predictive for prolonged survival. Again treat-
ments varied, with patients with stage I–IIIa being eligible for
complete resection, whereas stage IIIb–IV received chemotherapy
or RT. In their series of 70 patients with primary breast cancer,
Oshida et al (1998) reported that DAR was an independent
predictor of relapse-free survival. However, 58 patients received a
mastectectomy and 12 had breast conserving therapy. Other
groups have reported less convincing data. Minn et al (1997)
found in their series of 37 patients with squamous cell head and
neck cancer, the only independent prognostic factors were mitotic
count and stage, despite there being a significantly improved 3-
year OS in patients with a low SUV. Nakata et al (1997) studied a
series of 14 patients with adenocarcinoma of the pancreas. They
found a statistically significant prolonged survival in patients with
a low SUV. However, treatments were extremely varied with only
one patient receiving chemotherapy. A recent study by Higashi et
al (1999) examined the effect of intraoperative radiation therapy
(IORT) on FDG uptake in patients with adenocarcinoma of the
pancreas. Their results indicated that the measurement of the
average SUV in the tumour area could evaluate the local response
of pancreatic cancer after IORT earlier and more markedly than
with CT. However, they did not find a correlation with prognosis
in these patients. One explanation may be that only eight of the 12
patients in this series received systemic treatment with
chemotherapy. Changes in FDG uptake may therefore have
reflected local control of the disease rather than overall survival. In
the present study, although the numbers are small, all the patients
have identical histology and all patients received chemotherapy.
Whilst recognizing the potential of PET it is important not to
forget its limitations. Inflammatory tissue is recognized as a cause
of false-positive results. In particular, chronic pancreatitis,
cystadenoma, retroperitoneal fibrosis and lymphocyte infiltration
may lead to false-positive results in patients with pancreatic
masses (Bares et al, 1994; Inokuma et al, 1995). Despite this
problem, studies have demonstrated a high PPV of FDG-PET
(Bares et al, 1994; Zimny et al, 1997) suggesting that despite the
occurrence of FP results, FDG-PET still has the ability to success-
fully identify malignant lesions. Treatment-induced changes
(including RT and chemotherapy) have also been reported as a
cause of false-positive results (Strauss, 1996). There are also a
number of possible causes of false-negative results. FDG uptake
has been shown to correlate with tumour grade, and low grade
histology may be a cause of false-negative results (Rigo et al,
1996). Finally the sensitivity of the scanner will obviously have an
influence on the rate of false-negative results.
There are a number of limitations of this study. As a pilot study the
number of patients in this study is low and so although the results are
statistically significant, the statistical power is low. The timing of the
scans following therapy was chosen arbitrarily and may not be
optimal. It would be useful to perform a series of scans to address this
issue. Previous studies (Bares et al, 1994; Zimny et al, 1997) have
reported the sensitivity of FDG-PET in the detection of pancreatic
cancer to be 85–93%. The present study gave a sensitivity of 73%.
Although the difference in sensitivity between these studies may in
part be due to small numbers, the sensitivity of the MUP-PET cannot
equal that of a modern commercial scanner. Due to the low camera
sensitivity the uptake of FDG in small regions of tumour may be
underestimated and this may effect the measurement of the level of
response to treatment if the volume of the tumour changes substan-
tially. However, in this study, only relative quantification was used to
assess tumour response and, as most tumour sizes were greater than
the spatial resolution (Table 3), partial volume effects are unlikely to
substantially change the results.
Blood glucose was not routinely measured prior to PET scan-
ning. However, although raised blood glucose has been reported as
a cause of FN results, Zimney et al (1997) found no significant
difference in the SUV between euglycaemic and hyperglycaemic
patients in the 74 patients studied with histologically proven
adenocarcinoma of the pancreas. Stollfuss et al (1995) found that
of the 4 patients with pancreatic cancer who had FN findings, none
had diabetes or raised blood glucose.
Although attempts were made to optimize reproducibility and
positioning of the patients between studies FDG-PET scans, it
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possible source of error in any PET study.
In this study we have demonstrated a reduction in FDG uptake
in seven out of 11 patients with pancreatic cancer following the
commencement of chemotherapy, and that in the majority of
patients this predates any response (if any) as assessed by CT scan-
ning. Six patients had no FDG uptake at 1 month post treatment
and these patients had a statistically significant advantage in OS
compared to those with residual FDG uptake and possible correla-
tion to symptomatic improvement. The results of this study are
compatible with the limited published data and suggest that FDG-
PET may a useful tool in assessing early response to treatment and
predicting prognosis in pancreatic cancer.
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